The Therapeutic Potential of Stem Cell Therapy for Doxorubicin-Induced Cardiotoxicity: A Narrative Review.
Mirzaei A., Rezaei P., Vafa RG., Jahani S., Arefnezhad R., Fatemian H.
Laboratory Study on Cardiovascular Disease, Chronic Inflammation, published in Health Sci Rep (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Health Sci Rep (2026)
- Country
- United States
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42534466
- DOI
- 10.1002/hsr2.72924
Abstract (original English)
Doxorubicin (DOX) is a potent anthracycline chemotherapeutic agent whose clinical utility is significantly constrained by severe side effects, most notably DOX-induced cardiotoxicity (DIC). Pathophysiological mechanisms of DIC include oxidative stress, mitochondrial dysfunction, programmed cell death, and inflammation. Given the therapeutic potential of stem cell technology, this narrative review aims to summarize current evidence regarding the use of various stem cell types, particularly mesenchymal stem cells (MSCs), as a potential treatment for DIC. This study conducted a comprehensive review of the literature concerning stem cell-based therapies in the context of DIC. We evaluated evidence regarding both pluripotent stem cells (including embryonic and induced pluripotent stem cells) and multipotent adult stem cells (such as bone marrow, adipose, and umbilical cord-derived MSCs) to assess their role in mitigating DOX-induced cardiac damage. Current research indicates that stem cells, particularly MSCs, possess significant regenerative capabilities that may counteract the multifaceted pathophysiology of DIC. Evidence suggests that these cells can modulate inflammatory responses, alleviate oxidative stress, and support mitochondrial repair in damaged cardiac tissue, thereby offering a promising strategy to protect against or reverse chemotherapy-induced heart injury. Stem cell
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Factor XII-A New Therapeutic Target? A Systematic Review
Systematic Review on Cardiovascular Disease, Neuroinflammation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci1 citations - Level AMeta-analysisEurope PMC
Can cell-based therapies bridge the gap between research and reality in the treatment of myocarditis? A systematic review and meta-analysis
Meta-analysis on Cardiovascular Disease, published in Regen Ther (2026) — summary generated from the PubMed abstract.
- 2026
Regen Ther - Level AMeta-analysisEurope PMC
Efficacy and safety of stem cell therapy for myocardial infarction and heart failure: an updated systematic review and meta-analysis of randomized controlled trials
Meta-analysis with a reported sample of 3345 on Cardiovascular Disease, Stroke Research, published in Syst Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 3345
Syst Rev - Level AMeta-analysisEurope PMC
Orally derived mesenchymal stem cells in the treatment of vascular diseases: a systematic review and meta-analysis
Meta-analysis on Cardiovascular Disease, published in Sci Rep (2026) — summary generated from the PubMed abstract.
- 2026
Sci Rep - Level ASystematic ReviewEurope PMC
From Preservation to Repair: A Systematic Review of Therapeutic Organ Rehabilitation During Normothermic Ex Vivo Machine Perfusion
Systematic Review with a reported sample of 12 on Cardiovascular Disease, Immune Modulation, published in Transplant Direct (2026) — summary generated from the PubMed abstract.
- 2026
- n = 12
Transplant Direct - Level AMeta-analysisEurope PMC
Safety and Efficacy of Transendocardial Stem Cells Therapy in Chronic Ischemic Heart Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Meta-analysis on Cardiovascular Disease, Stroke Research, published in Curr Cardiol Rev (2025) — summary generated from the PubMed abstract.
- 2025
Curr Cardiol Rev